Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mebeverine hydrochloride, quantity: 135 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; microcrystalline cellulose; povidone; sodium starch glycollate type a; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose - apo-mebeverine tablets are indicated in the management of the irritable bowel syndrome ('irritable colon', 'spastic colon', 'functional bowel disorders', 'spastic constipation', 'nervous diarrhoea'). apo-mebeverine is used to treat the symptoms of this condition - i.e. abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - bella is indicated for use:,? as an oral contraceptive.,? for the treatment of moderate acne vulgaris in women who seek oral contraception.,? for the treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of ethinylestradiol/drospirenone 20 microgram/3 mg tablets for pmdd was not assessed beyond 3 cycles. ethinylestradiol/drospirenone 20 microgram/3 mg tablets have not been evaluated for treatment of pms (premenstrual syndrome) (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ethinylestradiol, quantity: 0.02 mg; drospirenone, quantity: 3 mg - tablet - excipient ingredients: polacrilin potassium; magnesium stearate; lactose monohydrate - drospirenone/ethinyloestradiol-alphapharm 3/20 is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg/ethinyloestradiol 20 ?g tablets for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg/ethinyloestradiol 20 ?g tablets has not been evaluated for treatment of pms (premenstrual syndrome) (see clinical trials).

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - mebeverine hydrochloride, quantity: 135 mg - tablet, sugar coated - excipient ingredients: purified talc; acacia; gelatin; povidone; magnesium stearate; carnauba wax; potato starch; sucrose; lactose monohydrate - colofac tablets are indicated in the management of the irritable bowel syndrome ( 'irritable colon', 'spastic colon', 'functional bowel disorders', 'spastic constipation', 'nervous diarrhoea'). colofac is used to treat the symptoms of this condition- i.e. abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - mebeverine hydrochloride, quantity: 135 mg - tablet, sugar coated - excipient ingredients: purified talc; acacia; gelatin; povidone; magnesium stearate; carnauba wax; potato starch; sucrose; lactose monohydrate - colese tablets are indicated in the management of the irritable bowel syndrome ( 'irritable colon', 'spastic colon', 'functional bowel disorders', 'spastic constipation', 'nervous diarrhoea'). colese is used to treat the symptoms of this condition- i.e. abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

le vet bv - phenobarbital - tablet - 12.5 mg/tablet - phenobarbital - dogs - neurological preparations

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

le vet bv - phenobarbital - tablet - 50 mg/tablet - phenobarbital - dogs - neurological preparations

Australia - englanti - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 1000 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; hypromellose; crospovidone; mannitol; purified talc; titanium dioxide; iron oxide yellow; magnesium stearate - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; titanium dioxide; magnesium stearate; iron oxide yellow; purified talc; crospovidone; povidone; hypromellose - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 850 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; microcrystalline cellulose; povidone; mannitol; crospovidone; hypromellose; iron oxide yellow; magnesium stearate - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.